Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1974 2
1975 1
1976 4
1977 3
1978 5
1979 8
1980 4
1981 5
1982 6
1983 9
1984 12
1985 8
1986 5
1987 12
1988 15
1989 15
1990 13
1991 10
1992 10
1993 14
1994 10
1995 11
1996 15
1997 15
1998 13
1999 15
2000 21
2001 17
2002 21
2003 12
2004 7
2005 11
2006 13
2007 14
2008 20
2009 21
2010 25
2011 24
2012 26
2013 27
2014 33
2015 26
2016 26
2017 23
2018 10
2019 12
2020 30
2021 26
2022 32
2023 33
2024 27

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

718 results

Results by year

Filters applied: . Clear all
Page 1
Movement disorders emergencies.
Munhoz RP, Scorr LM, Factor SA. Munhoz RP, et al. Among authors: factor sa. Curr Opin Neurol. 2015 Aug;28(4):406-12. doi: 10.1097/WCO.0000000000000212. Curr Opin Neurol. 2015. PMID: 26110802 Review.
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
Bohnen NI, Costa RM, Dauer WT, Factor SA, Giladi N, Hallett M, Lewis SJG, Nieuwboer A, Nutt JG, Takakusaki K, Kang UJ, Przedborski S, Papa SM; MDS-Scientific Issues Committee. Bohnen NI, et al. Among authors: factor sa. Mov Disord. 2022 Feb;37(2):253-263. doi: 10.1002/mds.28883. Epub 2021 Dec 22. Mov Disord. 2022. PMID: 34939221 Free PMC article. Review.
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH. Anderson KE, et al. Among authors: factor sa. Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28. Lancet Psychiatry. 2017. PMID: 28668671 Clinical Trial.
Editor's note.
Factor SM. Factor SM. Cardiovasc Pathol. 1996 Jul-Aug;5(4):193. doi: 10.1016/s1054-8807(96)90019-8. Cardiovasc Pathol. 1996. PMID: 25851572 No abstract available.
Lurasidone-Induced Tardive Syndrome.
Tripathi R, Reich SG, Scorr L, Guardiani E, Factor SA. Tripathi R, et al. Among authors: factor sa. Mov Disord Clin Pract. 2019 Jul 24;6(7):601-604. doi: 10.1002/mdc3.12812. eCollection 2019 Sep. Mov Disord Clin Pract. 2019. PMID: 31538095 Free PMC article.
718 results